Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0605
D

Failure to Monitor and Care Plan for Psychotropic Medication Use

Riverside, California Survey Completed on 05-09-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that three residents were free from unnecessary psychotropic medications and that appropriate monitoring and care planning were in place during the administration of these medications. Two residents were administered venlafaxine for depression without documented monitoring for potential adverse effects. In both cases, there were no care plans developed to guide nursing staff on how to monitor for side effects or evaluate the effectiveness of the medication, and provider orders to monitor for side effects were either missing or not implemented. The Quality Assurance nurse and the Director of Nursing confirmed the absence of care plans and monitoring orders, acknowledging that staff would not have clear guidance on managing or identifying side effects. Another resident was administered Seroquel for schizoaffective disorder without the required manufacturer-specified monitoring, such as lipid panels and thyroid function tests (TSH and Free T4). The medical record lacked documentation of these assessments, and both the QA nurse and DON confirmed that the necessary monitoring was not performed or recorded. The consultant pharmacist also acknowledged that the required monitoring should have been conducted during Seroquel use. The facility's own policy required ongoing evaluation of the effects of psychotropic medications, including monitoring for adverse consequences and following manufacturer specifications. However, the records reviewed showed that these procedures were not followed for the residents in question, resulting in the administration of psychotropic medications without appropriate monitoring or care planning as required by both facility policy and clinical standards.

An unhandled error has occurred. Reload 🗙